Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E77.05 EPS (ttm)0.43 Insider Own1.06% Shs Outstand48.84M Perf Week8.61%
Market Cap1.63B Forward P/E36.08 EPS next Y0.92 Insider Trans383.90% Shs Float48.35M Perf Month18.92%
Income21.35M PEG2.57 EPS next Q0.03 Inst Own105.57% Short Float13.33% Perf Quarter5.38%
Sales322.42M P/S5.05 EPS this Y-43.02% Inst Trans1.94% Short Ratio8.28 Perf Half Y-24.31%
Book/sh7.90 P/B4.22 EPS next Y60.42% ROA4.72% Short Interest6.45M Perf Year-41.24%
Cash/sh4.52 P/C7.37 EPS next 5Y30.00% ROE5.95% 52W Range26.66 - 73.13 Perf YTD6.73%
Dividend Est.- P/FCF- EPS past 5Y31.51% ROI5.11% 52W High-54.45% Beta0.83
Dividend TTM- Quick Ratio5.08 Sales past 5Y21.55% Gross Margin78.36% 52W Low24.97% ATR (14)1.70
Dividend Ex-Date- Current Ratio5.62 EPS Y/Y TTM-45.63% Oper. Margin8.71% RSI (14)60.43 Volatility6.92% 5.10%
Employees1115 Debt/Eq0.09 Sales Y/Y TTM13.37% Profit Margin6.62% Recom2.33 Target Price40.88
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q32.91% Payout0.00% Rel Volume0.92 Prev Close31.24
Sales Surprise0.43% EPS Surprise-27.29% Sales Q/Q19.09% EarningsFeb 26 AMC Avg Volume778.92K Price33.31
SMA209.61% SMA508.87% SMA200-19.67% Trades Volume717,452 Change6.63%
Date Action Analyst Rating Change Price Target Change
Dec-05-23Downgrade Needham Buy → Hold
Dec-04-23Initiated Morgan Stanley Equal-Weight $35
Sep-15-23Downgrade The Benchmark Company Buy → Hold
Aug-03-23Downgrade Canaccord Genuity Buy → Hold $77 → $48
Jun-07-23Downgrade William Blair Outperform → Mkt Perform
Apr-17-23Initiated Piper Sandler Neutral $65
Feb-06-23Downgrade BTIG Research Buy → Neutral
Dec-28-22Reiterated BTIG Research Buy $80 → $67
Dec-08-22Initiated Stifel Hold $60
Nov-07-22Upgrade Sidoti Neutral → Buy
Feb-28-24 10:58AM
Feb-27-24 02:00PM
Feb-26-24 05:30PM
04:01PM Loading…
Feb-19-24 07:00AM
Jan-27-24 01:03PM
Jan-23-24 07:00AM
Jan-12-24 06:49PM
Jan-08-24 07:00AM
Dec-17-23 12:35PM
Dec-05-23 03:16AM
Dec-04-23 04:05PM
Nov-15-23 07:00AM
05:50PM Loading…
Nov-02-23 05:50PM
Nov-01-23 06:30PM
Oct-31-23 04:40PM
Oct-18-23 04:05PM
Oct-17-23 07:00AM
Oct-13-23 06:30PM
Oct-10-23 10:51AM
Sep-19-23 11:51AM
Sep-15-23 09:32AM
Sep-14-23 12:53PM
11:38AM Loading…
Sep-08-23 11:38AM
Sep-07-23 05:00PM
Aug-18-23 10:40AM
Aug-17-23 06:48PM
Aug-09-23 07:00AM
Aug-07-23 07:00AM
Aug-03-23 07:18PM
Aug-02-23 05:25PM
Jul-19-23 07:00AM
Jun-21-23 08:00PM
Jun-13-23 08:00AM
May-26-23 06:00AM
May-17-23 10:10AM
May-09-23 01:48PM
May-04-23 07:00AM
May-03-23 05:35PM
Apr-27-23 10:02AM
Apr-26-23 08:00PM
Apr-23-23 08:25AM
Apr-19-23 07:00AM
Apr-07-23 11:44AM
Apr-04-23 06:00PM
Mar-29-23 06:00PM
Mar-23-23 06:00PM
Mar-15-23 05:50PM
Mar-13-23 08:48AM
Mar-09-23 05:25AM
Feb-23-23 05:12AM
Feb-21-23 05:15PM
Feb-13-23 05:50PM
Feb-07-23 07:00AM
Feb-03-23 05:50PM
Jan-31-23 09:25AM
Jan-25-23 06:00PM
Jan-24-23 03:26PM
Jan-17-23 06:00PM
Jan-11-23 07:00AM
Jan-10-23 06:41AM
Jan-09-23 07:00AM
Jan-06-23 09:13PM
Dec-30-22 07:17AM
Dec-20-22 08:56AM
Dec-19-22 08:15AM
Dec-13-22 11:01AM
Nov-28-22 01:18PM
Nov-17-22 07:00AM
Nov-13-22 09:28AM
Nov-11-22 08:38AM
Nov-02-22 05:25PM
Oct-29-22 10:49AM
Oct-24-22 12:45PM
Oct-19-22 07:00AM
Oct-12-22 07:00AM
Oct-07-22 12:45PM
Oct-02-22 10:45AM
Sep-19-22 01:39PM
Sep-17-22 08:48AM
Sep-14-22 07:00AM
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROADWOOD PARTNERS, L.P.10% OwnerJan 08Buy27.114,042109,57010,768,430Jan 10 05:44 PM
BROADWOOD PARTNERS, L.P.10% OwnerJan 05Buy28.48156,7344,463,23110,764,388Jan 05 07:07 PM
BROADWOOD PARTNERS, L.P.10% OwnerJan 04Buy28.9163,2461,828,18310,607,654Jan 05 07:07 PM
BROADWOOD PARTNERS, L.P.10% OwnerJan 03Buy28.936,573190,14410,544,408Jan 05 07:07 PM
Zhou Lilian YanshengDirectorDec 06Buy30.7485026,1292,327Dec 06 04:11 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 30Buy31.42177,7075,583,67810,537,835Nov 30 07:08 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 29Buy31.39160,3005,031,35810,360,128Nov 30 07:08 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 28Buy31.8596,9843,088,79410,199,828Nov 30 07:08 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 13Buy33.0450716,74910,102,844Nov 14 07:13 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 10Buy32.7334,3201,123,38310,102,337Nov 14 07:13 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 09Buy33.09140,0004,632,58110,068,017Nov 09 07:01 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 08Buy33.71139,4094,699,0739,928,017Nov 09 07:01 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 07Buy34.039,731331,1279,788,608Nov 09 07:01 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 06Buy34.16164,6075,623,5189,778,877Nov 06 07:01 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 03Buy36.0652018,7539,614,270Nov 06 07:01 PM
BROADWOOD PARTNERS, L.P.10% OwnerNov 02Buy35.79144,0275,155,2439,613,750Nov 06 07:01 PM
BROADWOOD PARTNERS, L.P.10% OwnerOct 06Buy37.6275,2992,832,4179,469,723Oct 06 07:43 PM
BROADWOOD PARTNERS, L.P.10% OwnerOct 05Buy37.9297,4743,696,3999,394,424Oct 06 07:43 PM
BROADWOOD PARTNERS, L.P.10% OwnerOct 04Buy37.9332,5231,233,6499,296,950Oct 06 07:43 PM
BROADWOOD PARTNERS, L.P.10% OwnerSep 21Buy39.62154,8146,133,4679,264,427Sep 21 08:31 PM
Lin Elizabeth YeuDirectorSep 21Buy40.002,500100,0002,855Sep 22 07:18 PM
BROADWOOD PARTNERS, L.P.10% OwnerSep 20Buy40.67132,0795,372,2749,109,613Sep 21 08:31 PM
BROADWOOD PARTNERS, L.P.10% OwnerSep 19Buy40.894,490183,6138,977,534Sep 21 08:31 PM
BROADWOOD PARTNERS, L.P.10% OwnerSep 07Buy41.2660,8742,511,7228,973,044Sep 07 07:00 PM
BROADWOOD PARTNERS, L.P.10% OwnerSep 06Buy41.43108,9444,513,7358,912,170Sep 07 07:00 PM
BROADWOOD PARTNERS, L.P.10% OwnerSep 05Buy41.8720,144843,4558,803,226Sep 07 07:00 PM
Williams Patrick F.Chief Financial OfficerAug 10Option Exercise0.005,122045,400Aug 11 06:01 PM
WEISNER AIMEE SDirectorAug 07Buy48.722,00097,4405,417Aug 07 04:16 PM
FARRELL STEPHEN CDirectorJun 15Option Exercise0.001,70908,276Jun 16 08:41 PM
Kliman Gilbert HDirectorJun 15Option Exercise0.003,41709,656Jun 16 08:39 PM
WEISNER AIMEE SDirectorJun 15Option Exercise0.003,41703,417Jun 16 08:37 PM
Yu K PeonyDirectorJun 15Option Exercise0.001,70902,786Jun 16 08:35 PM
Williams Patrick F.Chief Financial OfficerJun 06Option Exercise0.005,121047,387Jun 07 04:53 PM
Michna MagdaChief Clinical, Regulatory,May 08Option Exercise0.0014,047014,047May 09 05:26 PM
Foust WarrenChief Operating OfficerMay 08Option Exercise0.0020,331020,331May 09 05:24 PM
Holliday KeithChief Technology OfficerMar 17Sale61.9782351,00127,633Mar 17 06:04 PM
Barnes Scott DChief Medical OfficerMar 10Option Exercise0.0010,555040,810Mar 10 09:39 PM
Francese James ESr. VP, Comm. Ops., NA, APACMar 10Option Exercise0.008,388042,374Mar 10 09:38 PM
Gesten Samuel JChief Legal OfficerMar 10Option Exercise0.009,531043,219Mar 10 09:37 PM
Holliday KeithChief Technology OfficerMar 10Option Exercise0.0010,192028,456Mar 10 09:36 PM
Studholme RobertSenior VP, OperationsMar 10Option Exercise0.008,859031,980Mar 10 09:34 PM
Williams Patrick F.Chief Financial OfficerMar 10Option Exercise0.0012,184045,676Mar 10 09:35 PM
Williams Patrick F.Chief Financial OfficerMar 07Option Exercise58.131,71199,46035,492Mar 08 08:18 PM
Studholme RobertSenior VP, OperationsMar 07Option Exercise58.131,70999,34423,121Mar 08 08:18 PM
Barnes Scott DChief Medical OfficerMar 07Option Exercise58.131,60393,18232,143Mar 08 08:14 PM
Holliday KeithChief Technology OfficerMar 07Option Exercise58.131,43183,18419,979Mar 08 08:17 PM
Gesten Samuel JChief Legal OfficerMar 07Option Exercise58.131,33877,77835,306Mar 08 08:16 PM
Francese James ESr. VP, Comm. Ops., NA, APACMar 07Option Exercise58.131,08362,95535,319Mar 08 08:15 PM
Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
OCX Oncocyte Corporation daily Stock Chart
Index- P/E- EPS (ttm)- Insider Own8.02% Shs Outstand8.26M Perf Week-2.12%
Market Cap24.78M Forward P/E- EPS next Y-2.86 Insider Trans0.00% Shs Float7.60M Perf Month-3.23%
Income- PEG- EPS next Q-0.99 Inst Own54.91% Short Float2.40% Perf Quarter-21.05%
Sales- P/S- EPS this Y86.15% Inst Trans-33.80% Short Ratio13.66 Perf Half Y-20.58%
Book/sh4.55 P/B0.66 EPS next Y-56.70% ROA- Short Interest0.18M Perf Year-56.88%
Cash/sh1.72 P/C1.74 EPS next 5Y- ROE- 52W Range2.08 - 7.96 Perf YTD20.00%
Dividend Est.- P/FCF- EPS past 5Y-0.70% ROI- 52W High-62.31% Beta0.80
Dividend TTM- Quick Ratio2.11 Sales past 5Y6.09% Gross Margin- 52W Low44.23% ATR (14)0.15
Dividend Ex-Date- Current Ratio2.11 EPS Y/Y TTM-60.01% Oper. Margin-682.44% RSI (14)48.96 Volatility3.73% 3.90%
Employees76 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom2.33 Target Price3.53
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q44.84% Payout- Rel Volume0.75 Prev Close2.91
Sales Surprise37.28% EPS Surprise19.67% Sales Q/Q-79.25% EarningsNov 09 BMO Avg Volume13.38K Price3.00
SMA201.14% SMA50-1.67% SMA200-14.69% Trades Volume10,002 Change3.09%
Date Action Analyst Rating Change Price Target Change
May-24-22Downgrade Stephens Overweight → Equal-Weight
Mar-14-22Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jan-07-22Initiated Stephens Overweight $3.10
Jan-06-22Resumed Piper Sandler Overweight $3.10
Mar-17-21Resumed Needham Buy $8
Jan-07-21Upgrade The Benchmark Company Speculative Buy → Buy $6
Dec-16-20Upgrade Piper Sandler Neutral → Overweight $2 → $4
Nov-30-20Initiated BTIG Research Buy $5
Nov-10-20Initiated KeyBanc Capital Markets Overweight $5
Jul-30-20Reiterated The Benchmark Company Speculative Buy $7 → $6
Jan-16-24 08:00AM
Dec-06-23 08:00AM
Nov-09-23 08:27AM
Nov-03-23 08:30AM
08:00AM Loading…
Sep-18-23 08:00AM
Sep-06-23 08:00AM
Aug-28-23 08:30AM
Aug-10-23 07:00AM
Aug-09-23 08:00AM
Aug-08-23 08:30AM
Aug-03-23 08:00AM
Jul-25-23 09:08AM
Jul-24-23 01:35PM
Jun-27-23 08:30AM
04:15PM Loading…
Jun-01-23 04:15PM
May-11-23 08:00AM
Apr-27-23 04:59PM
Apr-18-23 08:45AM
Apr-12-23 04:15PM
Apr-07-23 08:24AM
Apr-03-23 08:00AM
Mar-31-23 05:00PM
Mar-29-23 04:01PM
Mar-15-23 04:01PM
Mar-02-23 09:00AM
Feb-22-23 08:00AM
Dec-16-22 08:19AM
Nov-30-22 06:05PM
06:00PM Loading…
Nov-10-22 04:30PM
Oct-27-22 04:01PM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-31-22 04:01PM
Aug-30-22 04:27PM
Aug-24-22 08:00AM
Aug-10-22 04:05PM
Aug-03-22 04:01PM
Aug-01-22 11:33AM
Jul-27-22 04:01PM
Jul-13-22 08:00AM
Jul-06-22 08:00AM
Jun-22-22 08:00AM
Jun-15-22 07:15AM
May-26-22 05:00PM
May-11-22 04:05PM
May-05-22 08:00AM
Apr-28-22 04:01PM
Apr-27-22 04:30PM
Apr-22-22 09:26AM
Apr-13-22 10:01PM
Apr-11-22 08:00AM
Mar-28-22 08:00AM
Mar-10-22 04:05PM
Mar-01-22 04:05PM
Feb-21-22 07:26AM
Feb-10-22 08:00AM
Jan-18-22 04:05PM
Jan-06-22 09:43AM
Jan-04-22 08:00AM
Dec-09-21 06:00PM
Dec-08-21 08:00AM
Dec-06-21 08:00AM
Dec-02-21 08:00AM
Nov-22-21 06:14AM
Nov-09-21 04:05PM
Nov-04-21 08:00AM
Nov-02-21 03:02PM
Oct-27-21 08:00AM
Oct-26-21 04:05PM
Oct-08-21 09:46AM
Oct-07-21 08:00AM
Sep-30-21 08:00AM
Sep-20-21 11:35AM
Sep-16-21 08:00AM
Sep-13-21 08:00AM
Sep-07-21 04:05PM
Aug-23-21 09:13AM
Aug-18-21 08:49AM
Aug-17-21 08:00AM
Aug-10-21 04:01PM
Aug-09-21 08:00AM
Aug-03-21 03:00PM
Jul-27-21 10:35AM
Jul-08-21 05:34AM
Jun-22-21 08:00AM
Jun-15-21 08:03AM
Jun-03-21 08:00AM
Jun-01-21 08:00AM
May-24-21 05:26AM
May-17-21 04:01PM
May-06-21 08:00AM
May-04-21 04:01PM
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KINGSLEY ALFRED DDirectorJun 14Buy0.2130,0006,447469,111Jun 15 08:13 PM
PURA VIDA INVESTMENTS, LLC10% OwnerApr 05Buy0.30663,000200,0278,090,202Apr 07 05:12 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 03Buy0.3026,827,6388,093,89850,181,335Apr 05 09:35 PM
Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
LCTX Lineage Cell Therapeutics Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-0.13 Insider Own0.60% Shs Outstand188.48M Perf Week7.77%
Market Cap209.21M Forward P/E- EPS next Y-0.14 Insider Trans- Shs Float187.35M Perf Month19.34%
Income-23.07M PEG- EPS next Q-0.04 Inst Own48.06% Short Float5.36% Perf Quarter9.90%
Sales8.77M P/S23.86 EPS this Y3.81% Inst Trans0.01% Short Ratio12.67 Perf Half Y-17.78%
Book/sh0.39 P/B2.85 EPS next Y5.94% ROA-19.44% Short Interest10.04M Perf Year-19.57%
Cash/sh0.22 P/C5.06 EPS next 5Y- ROE-31.37% 52W Range0.84 - 1.57 Perf YTD1.83%
Dividend Est.- P/FCF- EPS past 5Y1.87% ROI-32.83% 52W High-29.25% Beta1.27
Dividend TTM- Quick Ratio2.74 Sales past 5Y159.52% Gross Margin86.07% 52W Low31.92% ATR (14)0.07
Dividend Ex-Date- Current Ratio2.74 EPS Y/Y TTM53.40% Oper. Margin-285.11% RSI (14)54.54 Volatility5.41% 8.05%
Employees78 Debt/Eq0.05 Sales Y/Y TTM-36.19% Profit Margin-262.94% Recom1.43 Target Price4.83
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q-14.01% Payout- Rel Volume0.51 Prev Close1.04
Sales Surprise-52.04% EPS Surprise4.08% Sales Q/Q-58.44% EarningsMar 07 AMC Avg Volume792.38K Price1.11
SMA205.45% SMA502.51% SMA200-9.10% Trades Volume404,407 Change6.73%
Date Action Analyst Rating Change Price Target Change
Nov-02-22Initiated Robert W. Baird Outperform $5
Jun-14-22Initiated B. Riley Securities Buy $4
Aug-19-21Initiated Noble Capital Markets Outperform $8
Mar-31-21Initiated Cantor Fitzgerald Overweight $6
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Feb-09-24 09:15AM
Feb-06-24 09:15AM
Jan-16-24 08:00AM
08:00AM Loading…
Dec-18-23 08:00AM
Nov-11-23 04:02PM
Nov-10-23 02:13PM
Nov-09-23 04:01PM
Nov-01-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 05:14PM
Oct-11-23 08:00AM
Oct-05-23 08:00AM
08:00AM Loading…
Sep-19-23 08:00AM
Sep-13-23 08:00AM
Sep-11-23 08:00AM
Sep-06-23 09:40AM
Aug-29-23 08:00AM
Aug-13-23 06:39AM
Aug-11-23 09:43AM
Aug-10-23 05:15PM
Aug-09-23 08:50AM
Aug-08-23 06:40PM
Aug-03-23 08:00AM
Jul-24-23 08:00AM
May-22-23 08:00AM
12:02PM Loading…
May-16-23 12:02PM
May-11-23 05:35PM
May-09-23 08:00AM
May-04-23 06:15PM
Apr-26-23 08:00AM
Apr-18-23 08:00AM
Apr-10-23 07:57PM
Mar-30-23 08:00AM
Mar-28-23 03:57PM
Mar-20-23 08:00AM
Mar-11-23 03:00AM
Mar-10-23 06:33AM
Mar-09-23 05:25PM
Mar-06-23 08:00AM
Mar-02-23 09:55AM
Feb-22-23 09:46AM
Feb-08-23 08:00AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-17-22 12:00PM
Nov-10-22 06:35PM
Nov-08-22 05:45PM
Nov-03-22 08:00AM
Oct-31-22 08:00AM
Oct-10-22 08:00AM
Oct-04-22 08:00AM
Oct-03-22 08:00AM
Sep-19-22 07:00AM
Aug-15-22 08:00AM
Aug-12-22 09:30AM
Aug-11-22 04:05PM
Aug-08-22 06:05PM
Aug-04-22 08:00AM
Jul-14-22 08:45AM
Jun-02-22 08:00AM
May-16-22 10:25AM
May-12-22 06:05PM
May-11-22 05:55PM
May-10-22 10:15AM
May-05-22 05:25PM
May-03-22 08:00AM
Apr-26-22 08:00AM
Apr-25-22 08:00AM
Apr-13-22 08:00AM
Apr-11-22 08:00AM
Mar-24-22 08:00AM
Mar-21-22 10:14AM
Mar-14-22 08:00AM
Mar-10-22 06:25PM
Mar-01-22 08:00AM
Feb-28-22 05:25PM
Jan-24-22 08:00AM
Jan-04-22 08:00AM
Dec-20-21 06:03PM
Nov-30-21 08:00AM
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAILEY DON MDirectorFeb 08Buy1.0496,155100,001158,801Feb 08 07:00 PM
BROADWOOD PARTNERS, L.P.DirectorFeb 06Buy1.046,730,7707,000,00141,666,255Feb 08 06:58 PM
Jayasuriya AnulaDirectorDec 29Buy1.0910,00010,90010,000Jan 02 07:08 PM